-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Mydecine (OTC:MYCOF) and Lobe Sciences (OTCQB:LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body.
Mydecine's Patent On The MYCO-006 Family Of Compounds
Mydecine is a company developing innovative first- and-second-generation therapeutics for the treatment of PTSD, depression, anxiety, addiction and other mental health disorders. It has filed a new, full patent application covering the MYCO-006 family of novel short-acting MDMA analogs with the World Intellectual Property Organization.
The provisional patent application was done in July 2021. The family of MDMA-like compounds is intended to reduce harm and improve safety compared to MDMA, targeting a reduced duration with the same effects as traditional MDMA.
As Mydecine's chief scientific officer Rob Roscow expressed: "From Rick Ingrasc's early work in the early 70's and 80's with couples counseling, to MAPS more recent work with PTSD, MDMA has shown strong positive results removing interpersonal distrust and communication blocks without interfering with cognition. This effect allows therapy to be more effective."
Yet Roscow further clarified that "although MDMA has shown great promise, the effects of the drug last 8 or more hours which is not ideal for a traditional medical setting," which is why the company is aiming at developing healthcare treatments that may be accessible to a wider crowd.
Mydecine's chief medical officer Dr. Rakesh Jetly added: "Psychedelic-assisted psychotherapy utilizing classic MDMA can take upwards of 12 hours to complete one session and a large amount of resources. Under this model, therapists would only be able to treat 2-4 patients per month. Our hope is by decreasing the half-life of MDMA, we can create treatments that can be easily repeated at your typical healthcare facility in order to make accessible and affordable treatments for patients."
Lobe Sciences's Patents on Psilocybin And Psilocin Analogues
Life sciences psychedelics company Lobe Sciences (OTCQB:LOBEF) has filed a provisional patent that would cover the preparation and use of its stable psilocin proprietaries and analogues.
As CEO Philip Young explained, Lobe's patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule.
The company is pursuing drug development programs using two initial proprietary psilocin analogues: L-130, targeting neurological conditions such as severe anxiety, PTSD and brain traumas; and L-131, a new, psilocin-related chemical entity covered in the recently filed patent application, which is a drug candidate for a neurological disorder affecting children.
As well as drug development, Lobe is also focused on distributing non-hallucinatory doses of their therapeutics whether to patients' homes, to their physician's offices or to the emergency unit in local hospital settings.
Photo by Philipp Katzenberger on Unsplash
Mydecine (OTC:MYCOF) and Lobe Sciences (OTCQB:LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body.
黴菌素(場外交易:MYCOF)和葉狀科學(場外交易代碼:LOBEF),兩家迷幻藥物領域的公司已經提交了專利申請。這是獲得專利過程中的第一步,需要得到監督機構的批准。
Mydecine's Patent On The MYCO-006 Family Of Compounds
Mydecine公司關於myco-006系列化合物的專利
Mydecine is a company developing innovative first- and-second-generation therapeutics for the treatment of PTSD, depression, anxiety, addiction and other mental health disorders. It has filed a new, full patent application covering the MYCO-006 family of novel short-acting MDMA analogs with the World Intellectual Property Organization.
Mydecine是一家開發創新的第一代和第二代療法的公司,用於治療創傷後應激障礙、抑鬱、焦慮、成癮和其他精神健康障礙。該公司已提交了一項新的完整專利申請,涵蓋Myco-006系列新型短效MDMA類似物世界知識產權組織。
The provisional patent application was done in July 2021. The family of MDMA-like compounds is intended to reduce harm and improve safety compared to MDMA, targeting a reduced duration with the same effects as traditional MDMA.
臨時專利申請於2021年7月完成。這個MDMA類化合物家族與MDMA相比,旨在減少危害並提高安全性,目標是縮短持續時間,並具有與傳統MDMA相同的效果。
As Mydecine's chief scientific officer Rob Roscow expressed: "From Rick Ingrasc's early work in the early 70's and 80's with couples counseling, to MAPS more recent work with PTSD, MDMA has shown strong positive results removing interpersonal distrust and communication blocks without interfering with cognition. This effect allows therapy to be more effective."
ASMydecine的首席科學官Rob Roscoo表示:“發件人裏克·英格拉奇在70年代初和80年代初對夫妻諮詢的早期工作,到最近對創傷後應激障礙的工作,MDMA在消除人際間的不信任和溝通障礙的同時,不幹擾認知,顯示出了很強的積極效果。這種效果讓治療變得更有效。
Yet Roscow further clarified that "although MDMA has shown great promise, the effects of the drug last 8 or more hours which is not ideal for a traditional medical setting," which is why the company is aiming at developing healthcare treatments that may be accessible to a wider crowd.
然而,羅斯考進一步澄清説:“儘管MDMA顯示出了巨大的前景,但這種藥物的效果持續了8個小時或更長時間,這對於傳統的醫療環境來説並不理想,這就是為什麼該公司的目標是開發可能對更廣泛的人羣可及.
Mydecine's chief medical officer Dr. Rakesh Jetly added: "Psychedelic-assisted psychotherapy utilizing classic MDMA can take upwards of 12 hours to complete one session and a large amount of resources. Under this model, therapists would only be able to treat 2-4 patients per month. Our hope is by decreasing the half-life of MDMA, we can create treatments that can be easily repeated at your typical healthcare facility in order to make accessible and affordable treatments for patients."
Mydecine的首席醫療官Rakesh Jetly博士補充道:“使用經典MDMA的迷幻藥物輔助心理治療可能需要12小時以上才能完成一次療程和大量資源。。在這種模式下,治療師每月只能治療2-4名患者。我們希望通過減少MDMA的半衰期,我們可以創造出可以在你的典型醫療機構很容易重複的治療方法,以便為患者提供可獲得和負擔得起的治療。“
Lobe Sciences's Patents on Psilocybin And Psilocin Analogues
波普科學公司的P專利西洛菌素和西洛菌素類似物
Life sciences psychedelics company Lobe Sciences (OTCQB:LOBEF) has filed a provisional patent that would cover the preparation and use of its stable psilocin proprietaries and analogues.
生命科學迷幻藥公司葉科學(OTCQB:LOBEF)已經提交了一項臨時專利,將涵蓋其穩定的裸球菌素類藥物及其類似物的製備和應用.
As CEO Philip Young explained, Lobe's patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule.
AS首席執行官菲利普·楊據介紹,利普公司的專利組合現在包括裸蓋菇素、裸蓋菇素類似物和N-乙酰半胱氨酸(NAC)的使用和交付的多項專利申請,以及一項涵蓋裸蓋菇素分子多種專有穩定形式的用途和製備的新專利。
The company is pursuing drug development programs using two initial proprietary psilocin analogues: L-130, targeting neurological conditions such as severe anxiety, PTSD and brain traumas; and L-131, a new, psilocin-related chemical entity covered in the recently filed patent application, which is a drug candidate for a neurological disorder affecting children.
該公司正在使用兩種最初的專有psiLocin類似物進行藥物開發計劃:L-130,針對嚴重焦慮、創傷後應激障礙和腦部創傷等神經疾病;以及L-131,一種新的與psiLocin相關的化學實體,在最近提交的專利申請中涵蓋,這是一種治療影響兒童的神經疾病的候選藥物。
As well as drug development, Lobe is also focused on distributing non-hallucinatory doses of their therapeutics whether to patients' homes, to their physician's offices or to the emergency unit in local hospital settings.
除了藥物開發,LOPE還專注於分發他們治療藥物的非幻覺劑量無論是到病人家中,到他們的醫生辦公室,還是到當地醫院的急診室。
Photo by Philipp Katzenberger on Unsplash
圖片由Philipp Katzenberger在Unspash上拍攝
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧